Clinical Trial Update: Bioequivalence Study of Lisinopril and Hydrochlorothiazide Tablets (20+25) mg Under Fasting Conditions [Phase 1]

View source ↗

Summary

A Phase 1 bioequivalence study of fixed-dose lisinopril/hydrochlorothiazide tablets (20 mg/25 mg) under fasting conditions has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Lisinopril/Hydrochlorothiazide tablets (20 mg/25 mg) (lisinopril/hydrochlorothiazide)

Snippet

Sponsor: IPCA Laboratories Ltd. | Conditions: Fasting | Phase 1 | Status: COMPLETED